Earnings Winners & Losers: BSX, BCR, EW, PHG, SYK, TFX, TMO

 
• By Tina Tan
  
Generate a summary of this article
Listen to this article
Beta

The earnings season is now in full swing with more large-cap medtech stocks releasing their quarterly results. This week we spotlight cardiology market leaders Boston Scientific and Edwards Lifesciences, big ortho hitter Stryker, specialty diagnostics provider Thermo Fisher, and diversified players such as Philips, Bard and Teleflex. But which among them are this season's earnings winners and losers?

Economics graph
Medtech quarterly earnings • Source: shutterstock.com

This week saw several medtech sector leaders put out their quarterly earnings and performances, and at first glance they look to be solid overall. Among the list of large-cap players listed below (see Table 1), none reported shrinking revenue while net incomes look to have widened comfortably. Boston Scientific, Edwards Lifesciences and Stryker all reported double-digit topline growth for the third quarter, while CR Bard, Philips HealthTech. Teleflex and Thermo Fisher's specialty diagnostics business reported more modest, single-digit increases. However, a deeper dive shows not all is what it seems. These are who we believe to be the real winners and losers:

CR Bard Inc. (BCR) has raised its financial guidance for 2016 again following an encouraging third quarter which saw...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Archive

Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

Cardiac catheter reuse targeted by FDA; lab testing of used catheters planned.

REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.

Heart valve sewing cuffs to be developed:

St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.

Nissho sales flat at only 1% in 1997:

Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.

More from Medtech Insight

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says - Clone

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

US Original PMAs and Panel-Track Supplementss

 
• By Olga Zviezdicheva, Reed Miller, and Nabil

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.